112
Participants
Start Date
April 23, 2020
Primary Completion Date
April 14, 2025
Study Completion Date
April 14, 2025
SRK-181
anti-latent TGFβ1 monoclonal antibody
anti-PD-(L)1 antibody therapy
approved anti-PD-(L)1 antibody therapy for each tumor type
Stony Brook University Cancer Center, Stony Brook
Seoul National University - Bundang Hospital, Seongnam-si
Memorial Cancer Institute - South Broward Hospital District, Hollywood
H. Lee Moffitt Cancer Center& Research Institute, Tampa
Advent Health, Celebration
Tennessee Oncology, Sarah Cannon Research Institute, Nashville
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
University of Michigan, Ann Arbor
Henry Ford Cancer Institute, Detroit
Medical College of Wisconsin, Milwaukee
University of Chicago, Chicago
BUMC Mary Crowley Cancer Research Centers, Dallas
The University of Texas - MD Anderson Cancer Center, Houston
The Oncology Institute, Los Angeles
University of California - San Diego, La Jolla
Korea University Ansan Hospital, Ansan-si
Hoag Memorial Hospital Presbyterian, Newport Beach
St. Jude Crosson Cancer Institute, Fullerton
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Scholar Rock, Inc.
INDUSTRY